2026年Biomedtracker数据监测医疗保健预ASCO报告

May2026 Summary Abstractsfromthe2026AnnualMeetingoftheAmericanSocietyofClinicalOncology(ASCO)werereleasedMay21stat 5pm ET. The 2025 ASCO meeting will be held in Chicago from May 29th-June 2rd, 2026. Wehave highlighted somekey abstracts with analyses. Included at theend of the report is alist of theASCO dataevents we have added from the Thursday release and Friday morning announcements. While this is just a briefoverview,wewillbeavailabletodiscussanydataofinterestinfurtherdetail.PleaseemailBiomedtrackerorcallyoursalesrepresentative. Additionally, keep an eye out for our ASCO weekend updates and live-coverage when themeeting takes place. Asareminder,ourASCO coveragewillcontinuethroughouttheconferenceandbeyond.Ourcoveragewillinclude: May31st-ASCOWeekendUpdateShortlyfollowing theconference-Post-ASCOReportandPodcast AbouttheAuthor Biomedtrackeris an independent research service that offers proprietary clinical assessments and patient-basedrevenue forecasts of developmental drugswithin a comprehensive and intuitive drug information database. Clientsfrom the pharmaceutical, biotech, andinvestmentindustriesrely on Biomedtrackerforitsinsight onthelikelihood ofapproval,commercialpotential,andfuturedataandregulatorycatalystsfordrugswithinthecompetitivelandscapeofevery important disease and indication. Over the last several years, Biomedtracker has become the leader inprovidingobjectiveinformationalongsideevidencebased clinical assessmentsandinvestmentresearchonpipelinedrugs worldwide. For more information on getting direct access to Biomedtracker, please emailclientservices@evaluate.com. Disclaimer Copyright©2026Evaluate,aNorstellacompany This report is published by Evaluate (the Publisher). This report contains information from reputable sources andalthough reasonable efforts havebeenmade to publish accurateinformation, you assume sole responsibility for theselection,suitabilityanduseof thisreportandacknowledgethatthePublishermakesnowarranties(eitherexpressorimplied) as to, nor accepts liability for, the accuracy orfitness for a particular purpose of the information or advicecontained herein. The Publisherwishes to make it clear that any views or opinions expressed in this report byindividual authors or contributors are their personal views and opinions and do not necessarily reflect theviews/opinions of the Publisher. TableofContents puxitatugsamrotecanforBiliaryTractCancer...................................................................................5rilvegostomigforBiliaryTractCancer................................................................................................8ZeleforBladderCancer...................................................................................................................11giredestrantforBreastCancer.........................................................................................................14DatrowayforBreastCancer............................................................................................................17EnhertuforBreastCancer...............................................................................................................21KisqaliforBreastCancer..................................................................................................................24giredestrantforBreastCancer.........................................................................................................27LumakrasforColorectalCancer(CRC)..............................................................................................30VectibixforColorectalCancer(CRC).................................................................................................33VectibixforColorectalCancer(CRC).................................................................................................36ZiiheraforEsophagealCancer..........................................................................................................39ZiiheraforGastricCancer................................................................................................................42EnhertuforGastricCancer..............................................................................................................45bezuclastinibforGastrointestinalStromalTumor(GIST)..................................................................48CRB-701forHeadandNeckCancer.................................................................................................52RybrevantforHeadandNeckCancer..............................................................................................56BelrestotugforHeadandNeckCancer............................................................................................59ASP-1929forHeadandNeckCancer...............................................................................................62JemperliforHeadandNeckCancer.................................................................................................65SI-B001forH